• Falk R. Ochsendorf


Systemic Lupus Erythematosus Chronic Fatigue Syndrome Ideal Body Weight Cutaneous Lupus Erythematosus Maximal Daily Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723–731Google Scholar
  2. Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH (2004) Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 13:119–124CrossRefPubMedGoogle Scholar
  3. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75–83PubMedGoogle Scholar
  4. Asch PH, Caussade P, Marquart-Elbaz C, Boehm N, Grosshans E (1997) Chloroquine-induced achromotrichia. An ultrastructural study. Ann Dermatol Venereol 124:552–556PubMedGoogle Scholar
  5. Avina-Zubieta JA, Galindo-Rodriguez S, Newman S, Suarez-Almazor ME, Russell AS (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57: 582–587PubMedGoogle Scholar
  6. Baguet JP, Tremel F, Fabre M (1999) Chloroquine cardiomyopathy with conduction disorders. Heart 81:221–223PubMedGoogle Scholar
  7. Barthel HR, Meier LG, Wallace DJ (1996) Antimalariamittel bei rheumatischen Erkrankungen. Dtsch med Wschr 121:1576–1582PubMedGoogle Scholar
  8. Bauer F (1981) Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential. A review. J Am Acad Dermatol 4:239–248PubMedGoogle Scholar
  9. Becerra-Cunat JL, Coll-Canti J, Gelpi-Mantius E, Ferrer-Avelli X, Lozano-Sanchez M, Millan-Torne M, Ojanguren I, Ariza A, Olive A (2003) Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy. Two case reports. Rev Neurol 36:523–526PubMedGoogle Scholar
  10. Benagiano G (2001) Non-surgical female sterilization with quinacrine: an update. Contraception 63:239–245CrossRefPubMedGoogle Scholar
  11. Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703–2706PubMedGoogle Scholar
  12. Boelaert JR, Piette J, Sperber K (2001) The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 20:137–140CrossRefPubMedGoogle Scholar
  13. Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780–785PubMedGoogle Scholar
  14. Borden MB, Parke AL (2001) Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24:1055–1063PubMedGoogle Scholar
  15. Callaway JL (1979) Late sequelae of quinacrine dermatitis, a new premalignant entity. J Am Acad Dermatol 1:456–457PubMedGoogle Scholar
  16. Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med 324:150–154Google Scholar
  17. Canadian rheumatology association (2000) Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 27:2919–2921Google Scholar
  18. Carmichael SJ, Charles B, Tett SE (2003) Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 25:671–681CrossRefPubMedGoogle Scholar
  19. Chung HS, Hann SK (1997) Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 24:569–572PubMedGoogle Scholar
  20. Clegg DO, Dietz F, Duffy J, Willkens RF, Hurd E, Germain BF, Wall B, Wallace DJ, Bell CL, Sleckman J (1997) Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 24:1896–1902PubMedGoogle Scholar
  21. Clemessy JL, Taboulet P, Hoffmann JF, Hantson P, Barriot P, Bismuth C, Baud J (1996) Treatment of acute chloroquine poisoning: a 5-year experience. Critical Care Med 24:1189–1195CrossRefGoogle Scholar
  22. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong du LT, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a controll group. Arthritis Rheum 48:3207–3211CrossRefPubMedGoogle Scholar
  23. D’Cruz D (2001) Antimalarial therapy: a panacea for mild lupus? Lupus 10:148–151CrossRefPubMedGoogle Scholar
  24. Dereure O, Guilhou JJ (2002) Eosinophilic-like erythema: a clinical subset of Well’s eosinophilic cellulitis responding to antimalarial drugs? Ann Dermatol Venereol 129:720–723PubMedGoogle Scholar
  25. Dubois EL (1976) Lupus erythematosus, 2nd edn. University of Southern California Press, Los Angeles, pp 548, 588Google Scholar
  26. Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokin 31:257–274Google Scholar
  27. Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology: an update. Dermatol Clin 16:235–251CrossRefPubMedGoogle Scholar
  28. Easterbrook M (1985) The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans Opthalmol Soc UK 104:204–207Google Scholar
  29. Engel GL, Romano J, Ferris Eb (1947) Effect of quinacrine on the central nervous system. Arch Neurol 58:337–350Google Scholar
  30. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41:924–929CrossRefPubMedGoogle Scholar
  31. Espinola RG, Pierangeli SS, Ghara AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518–522PubMedGoogle Scholar
  32. Feldmann R, Salomon D, Saurat JH (1994) The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189:425–427PubMedGoogle Scholar
  33. Ferrante A, Rowan-Kelly B, Seow WK, Thong YH (1986) Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 85:125–130Google Scholar
  34. Fox RI, Dixon R, Guarrassi V, Krubel S (1996) Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(Suppl 6):S31–S36PubMedGoogle Scholar
  35. Fries JF, Williams CA, Ramey DR, Block DA (1993) The relative toxicity of the disease-modifying antirheumatic drugs. Arthritis Rheum 36:297–306PubMedGoogle Scholar
  36. Humphreys F, Mrks JM (1988) Mepacrine and pregnancy. Br J Dermatol 118:452PubMedGoogle Scholar
  37. Jancinova V, Nosal R, Drabikova K, Danihelovaa E (2001) Cooperation of chloroquine and blood platelets in inhibition of polymorphonuclear leukocyte chemiluminescence. Biochem Pharmacol 62:1629–636CrossRefPubMedGoogle Scholar
  38. Jeong JY, Choi JW, Jeon KI, Jue DM (2002) Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 105:83–91CrossRefPubMedGoogle Scholar
  39. Jessop S, Whitelaw D, Jordaan F (2004) Drugs for discoid lupus erythematosus (Cochrane Review). In: The Cochrane Library, Issue 2, Chichester, UK, Y. Wiley & Sons Ltd.Google Scholar
  40. Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983–987CrossRefPubMedGoogle Scholar
  41. Johansen PB, Gran JT (1998) Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 16:472–474PubMedGoogle Scholar
  42. Jones SK (1999) Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140:3–7CrossRefPubMedGoogle Scholar
  43. Jordan P, Brookes JG, Nikolic G, Le Couteur DG (1999) Hydroxychloroquine overdose: toxicokinetics and management. J Toxicol Clin Toxicol 37:861–864CrossRefPubMedGoogle Scholar
  44. Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, Dispersio JF (2003) Hydroxychloroquine for the prevention of acute graft-versushost disease after unrelated donor transplantation. Biol Blood Marrow Transplant 9:714–721CrossRefPubMedGoogle Scholar
  45. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Ito S, Buncic RJ (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813–814CrossRefPubMedGoogle Scholar
  46. Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokin 30:263–299Google Scholar
  47. Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus — a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033–1041PubMedGoogle Scholar
  48. Laaksonen AL, Koskiahde V, Juva K (1974) Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 3:103–109PubMedGoogle Scholar
  49. Leigh JM, Kennedy CTC, Ramsey JD, Henderson WJ (1979) Mepacrine pigmentation in systemic lupus erythematosus. Br J Dermatol 101:147–153PubMedGoogle Scholar
  50. Levy GD, Munz SJ, Paschal J (1997) Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 40:1482–1486PubMedGoogle Scholar
  51. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, Albuquerque EM, Jesus NR (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401–404CrossRefPubMedGoogle Scholar
  52. Liu ST, Wang CR, Yin GD, Liu MF, Lee GL, Chen MY, Chuang CY, Chen CY (2001) Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 19:29–35PubMedGoogle Scholar
  53. Loudon JR (1988) Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Amer J Med 85(Suppl 4a):57–61CrossRefGoogle Scholar
  54. Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75(Suppl):40–45CrossRefGoogle Scholar
  55. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R (1994) Fulminant hepatic failure secondary to hydroxychloroquine. Gut 35:569–570PubMedGoogle Scholar
  56. Maksymowych W, Russell AS (1987) Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16:206–221CrossRefPubMedGoogle Scholar
  57. Malcangi G, Fraticelli P, Palmieri C, Cappelli M, Danieli MG (2000) Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. Rheumatol Int 20:31–33CrossRefPubMedGoogle Scholar
  58. Marquardt K, Albertson TE (2001) Treatment of hydroxychloroquine overdose. Am J Emerg Med 19:420–424CrossRefPubMedGoogle Scholar
  59. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reapparaisal. Ophthalmology 110:1321–1326CrossRefPubMedGoogle Scholar
  60. McDuffie FC (1965) Bone marrow depression after drug therapy in patients with systemic lupus erythematosus. Ann Rheum Dis 24:289–292PubMedGoogle Scholar
  61. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E (1996) Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 5:237–241PubMedGoogle Scholar
  62. Metayer I, Balguerie X, Courville P, Lauret P, Joly P (2001) Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 128:729–731PubMedGoogle Scholar
  63. Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ (1987) Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 30:567–571PubMedGoogle Scholar
  64. Minzi OM, Rais M, Svensson JO, Gustafsson LL, Ericsson O (2003) High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 783:473–480PubMedGoogle Scholar
  65. Mitja K, Izidor K, Music E (2000) Chloroquine-induced drug hypersensitivity alveolitis. Pneumologie 54:395–397CrossRefPubMedGoogle Scholar
  66. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, Amit-Vazina M (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11:356–361CrossRefPubMedGoogle Scholar
  67. Morgan KW, Callen JP (2001) Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 28:2129–2132PubMedGoogle Scholar
  68. Murphy M, Carmichael AJ (2001) Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 26:457–458CrossRefPubMedGoogle Scholar
  69. Nguyen K, Washenik K, Shupack J (2002) Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 45:S34–36CrossRefGoogle Scholar
  70. [No authors listed] (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Amer J Med 98:156–168Google Scholar
  71. Nord JE, Shah PK, Rinaldi RZ, Weisman MH (2004) Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 33:336–351CrossRefPubMedGoogle Scholar
  72. Ochsendorf FR, Runne U(1991) Chloroquin und Hydroxychloroquin: Nebenwirkungsprofil wichtiger Therapeutika. Hautarzt 42:140–146PubMedGoogle Scholar
  73. Ochsendorf FR, Runne U (1991) Subakute Chloroquin-Überdosierung: Schwindel, körperliche Schwäche, bullöse Lichtreaktion, Sehstörungen und generalisierte Weißfärbung der Haare. Dtsch med Wschr 116:1513–1516PubMedGoogle Scholar
  74. Ochsendorf FR, Runne U, Goerz G, Zrenner E (1993) Chloroquin-Retinopathie: durch individuelle Tagesdosis vermeidbar. Dtsch Med Wochenschr 118:1895–1898PubMedGoogle Scholar
  75. Ochsendorf FR, Runne U (1997) Therapie des systemischen Lupus erythematodes. Dtsch Med Wochenschr 122:877PubMedGoogle Scholar
  76. O’Dell JC, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff J, Garwood V, Maloley P, Klassen L, Wees S, Klein H, Moore G (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications. New Engl J Med 344:1287–1291CrossRefGoogle Scholar
  77. O’Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 46:1164–1170CrossRefPubMedGoogle Scholar
  78. Onigbogi O, Ajayi AA, Ukponmwan OE (2000) Mechanisms of chloroquine-induced body-scratching behavior in rats: evidence of involvement of endogenous opioid peptides. Pharmacol Biochem Behav 65:333–337CrossRefPubMedGoogle Scholar
  79. Onyeji CO, Ogunbona FA (2001) Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Eur J Pharm Sci 13:195–201PubMedGoogle Scholar
  80. Orteu CH, Buchanan JA, Hutchison I, Leigh IM, Bull RH (2001) Systemic lupus erythematosus presenting with oral mucosal lesions: easily missed? Br J Dermatol 144:1219–1223PubMedGoogle Scholar
  81. Ostensen M, Ramsey-Goldman R (1998) Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 19:389–410PubMedGoogle Scholar
  82. Parke AL, West B (1996) Hydroxychloroquine in pregnant patients with SLE. J Rheumatol 23:1715–1718PubMedGoogle Scholar
  83. Petri M (1996) Hydroxychloroquine use in the Baltimore lupus cohort. Effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22PubMedGoogle Scholar
  84. Pinckers A, Broekhuyse RM (1983) The EOG in rheumatoid arthritis. Acta Ophthalmol 61:831–837Google Scholar
  85. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN (1999) The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26:325–330PubMedGoogle Scholar
  86. Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M (2004) Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 34:182–186PubMedGoogle Scholar
  87. Reuss-Borst M, Berner B, Wulf G, Muller GA (1999) Complete heart block as a rare complication of treatment with chloroquine. J Rheumatol 26:1394–1395PubMedGoogle Scholar
  88. Rigaudiere F, Ingster-Moati I, Hache JC, Leid J, Verdet R, Haymann P, Rigolet MH, Zanlonghi X, Defoort S, Le Gargasson JF (2004) Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophthalmol 27:191–199Google Scholar
  89. Ruiz-Irastorza G, Khamashta MA, Hughes GR (2000) Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 9:1581–1593PubMedGoogle Scholar
  90. Runne U, Ochsendorf FR, Schmid K, Raudonat HW (1992) Sequential concentration of chloroquine in human hair correlates with ingested dose and duration of therapy. Acta Derm Venereol (Stockh) 72:355–357PubMedGoogle Scholar
  91. Savarino A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity of chloroquine. J Clin Virol 20:131–135CrossRefPubMedGoogle Scholar
  92. Scherbel AL, Mackenzie AH, Nousek JE, Adtjian M (1965) Ocular Lesions in Rheumatoid Arthritis and Related Disorders with Particular Reference to Retinopathy. N Engl J Med 273: 360–366Google Scholar
  93. Sontheimer RD (2000) Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. Arch Dermatol 136:1044–1049CrossRefPubMedGoogle Scholar
  94. Stein M, Bell MJ, Ang LC (2000) Hydroxychloroquine neuromyotoxicity. J Rheumatol 27: 2927–2931PubMedGoogle Scholar
  95. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27:2142–2145PubMedGoogle Scholar
  96. Tett SE, McLachlan AJ, Cutler DJ, Day RO (1994) Pharmacokinetics and pharmacodynamis of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6:355–359CrossRefPubMedGoogle Scholar
  97. Toubi E, Rosner I, Rozenbaum M, Kessel A, Golan TD (2000) The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9:92–95CrossRefPubMedGoogle Scholar
  98. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cidicino A, Danoff D, Osterland CK, Yeadon C, Smith CD (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian hydroxychloroquine study group. Lupus 7:80–85CrossRefPubMedGoogle Scholar
  99. Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2:19–23PubMedGoogle Scholar
  100. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C (2000) Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases. Presse Med 29:1596–1599PubMedGoogle Scholar
  101. von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P (2000) Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus. Hautarzt 51:82–85CrossRefPubMedGoogle Scholar
  102. Walker O, Ademowo OG (1996) A rapid, cost-effective liquid-chromatographic method for the determination for chloroquine and desethylchloroquine in biological fluids. Therap Drug Monitor 1:92–96CrossRefGoogle Scholar
  103. Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18:282–296CrossRefPubMedGoogle Scholar
  104. Wallace DJ, Linker-Israeli M, Methger AL, Stecher VM (1993) The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2(Suppl 1):S13–S15PubMedGoogle Scholar
  105. Wallace DJ (1996) The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5(Suppl 1):S59–S64PubMedGoogle Scholar
  106. Wallace DJ (2000) Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 9:81–82CrossRefPubMedGoogle Scholar
  107. Weber F, Schmuth M, Fritsch P, Sepp N (2001) Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol 144:292–296CrossRefPubMedGoogle Scholar
  108. Wechsler B, Le Thi Huong D, Piette JC (1999) Pregnancy and systemic lupus erythematosus. Ann Med Interne (Paris) 150:408–418Google Scholar
  109. Williams HJ, Egger MJ, Szinger JZ, Willkens RF, Kalunian KC, Clegg DO, Skosey JL, Brooks RH, Alarcon GS, Steen VD, Polisson RP, Ward JR (1994) Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 21:1457–1462PubMedGoogle Scholar
  110. Wollheim FA, Hanson A, Laurell CB (1978) Chloroquine treatment in rheumatoid arthritis. Scand J Rheumatol 7:171–176PubMedGoogle Scholar
  111. Zeidler GS (1995) Chloroquin (ResochinR) Synoptische Darstellung eines Pharmakons und seiner Indikation in der Medizin, speziell in der Dermatologie. In: Hautklinik. Düsseldorf: Heinrich-Heine University, Inaugural DissertationGoogle Scholar
  112. Ziering CL, Rabinowith LG, Esterly NB (1993) Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 28:764–770PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2005

Authors and Affiliations

  • Falk R. Ochsendorf

There are no affiliations available

Personalised recommendations